Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 6 h ago

Forte Biosciences, Inc.: ORBIMED ADVISORS LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Orbimed Advisors LLC amended its Schedule 13G filing on Forte Biosciences Inc., disclosing a change in its passive stake in the clinical-stage biotech. The amendment was filed with the SEC under accession number 0000947871-26-001031. Schedule 13G filings are used by investors holding stakes of 5% or more to report passive positions, and amendments typically signal a shift in holdings. The specific size of Orbimed's adjusted position and the direction of the change were not detailed in the filing headline. Investors will watch for further 13G or 13D filings to gauge whether Orbimed's position continues to evolve.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Orbimed Advisors LLC, Forte Biosciences, Inc.